Matches in Wikidata for { <http://www.wikidata.org/entity/Q72823659> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q72823659 description "article scientifique publié en 1994" @default.
- Q72823659 description "artículu científicu espublizáu en payares de 1994" @default.
- Q72823659 description "im November 1994 veröffentlichter wissenschaftlicher Artikel" @default.
- Q72823659 description "scientific article published on 01 November 1994" @default.
- Q72823659 description "wetenschappelijk artikel" @default.
- Q72823659 description "наукова стаття, опублікована в листопаді 1994" @default.
- Q72823659 name "A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial" @default.
- Q72823659 name "A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial" @default.
- Q72823659 type Item @default.
- Q72823659 label "A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial" @default.
- Q72823659 label "A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial" @default.
- Q72823659 prefLabel "A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial" @default.
- Q72823659 prefLabel "A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial" @default.
- Q72823659 P1433 Q72823659-8DC006A6-9E17-4F3A-A215-377AC8DA0F21 @default.
- Q72823659 P1476 Q72823659-A0F08C33-F5D7-4FDB-9467-67FC0FE4B237 @default.
- Q72823659 P2093 Q72823659-082C7E44-3E4B-4607-8C46-14FC225E18F2 @default.
- Q72823659 P2093 Q72823659-8025B018-1E7B-48E3-9DB4-9C97BDE47798 @default.
- Q72823659 P2093 Q72823659-876D4F32-8050-4C69-B4A8-233E62CB723F @default.
- Q72823659 P2093 Q72823659-9275C03B-90A3-46C9-AC4D-52E63F4294BF @default.
- Q72823659 P2093 Q72823659-BCE2A536-692D-4B9B-A9CC-730AD80F2A3B @default.
- Q72823659 P2093 Q72823659-CADD315D-DF48-47F3-9950-C0912FD903E3 @default.
- Q72823659 P2093 Q72823659-CB4EE16F-5EA7-4011-B76B-4388F8A5AE10 @default.
- Q72823659 P304 Q72823659-10E124B6-94F2-47B8-B919-D868CDE6F837 @default.
- Q72823659 P31 Q72823659-FAD9C75B-7BC2-4A60-87CC-6CFAE5D7EB20 @default.
- Q72823659 P433 Q72823659-A7CA7E61-773C-4A16-A6D8-75ADB52C8899 @default.
- Q72823659 P478 Q72823659-F0581AA6-84B4-45D7-8F44-C4A5B38B8F8C @default.
- Q72823659 P577 Q72823659-21A190D9-2F4C-4A62-A84C-B7167682C5B1 @default.
- Q72823659 P698 Q72823659-D131F73F-615C-4627-9517-F1BC9C06D521 @default.
- Q72823659 P921 Q72823659-24B622C3-82D4-4442-AE24-F2A80665E02C @default.
- Q72823659 P921 Q72823659-7427EF83-20A5-40F5-B023-9F35FF44D5B2 @default.
- Q72823659 P921 Q72823659-78C6D8E8-81A3-42F6-94E6-69C036107138 @default.
- Q72823659 P698 7967730 @default.
- Q72823659 P1433 Q6534498 @default.
- Q72823659 P1476 "A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial" @default.
- Q72823659 P2093 "Bartolucci AA" @default.
- Q72823659 P2093 "Martelo O" @default.
- Q72823659 P2093 "McCarley DL" @default.
- Q72823659 P2093 "Moore J" @default.
- Q72823659 P2093 "Omura GA" @default.
- Q72823659 P2093 "Stagg M" @default.
- Q72823659 P2093 "Vogler WR" @default.
- Q72823659 P304 "1847-1853" @default.
- Q72823659 P31 Q13442814 @default.
- Q72823659 P433 "11" @default.
- Q72823659 P478 "8" @default.
- Q72823659 P577 "1994-11-01T00:00:00Z" @default.
- Q72823659 P698 "7967730" @default.
- Q72823659 P921 Q180983 @default.
- Q72823659 P921 Q418817 @default.
- Q72823659 P921 Q42824827 @default.